A detailed history of Rockefeller Capital Management L.P. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 34,023 shares of VKTX stock, worth $1.76 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
34,023
Previous 16,269 109.13%
Holding current value
$1.76 Million
Previous $862,000 149.77%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $884,859 - $1.25 Million
17,754 Added 109.13%
34,023 $2.15 Million
Q2 2024

Aug 12, 2024

BUY
$47.39 - $80.2 $770,987 - $1.3 Million
16,269 New
16,269 $862,000
Q2 2023

Aug 14, 2023

BUY
$14.84 - $24.79 $111,700 - $186,594
7,527 New
7,527 $122,000
Q3 2022

Nov 02, 2022

SELL
$2.55 - $3.89 $8,925 - $13,615
-3,500 Reduced 70.55%
1,461 $3,000
Q2 2022

Aug 12, 2022

BUY
$2.11 - $3.15 $5,142 - $7,676
2,437 Added 96.55%
4,961 $14,000
Q4 2021

Feb 14, 2022

SELL
$4.6 - $6.72 $3,219 - $4,704
-700 Reduced 21.71%
2,524 $11,000
Q3 2021

Nov 12, 2021

BUY
$5.58 - $7.04 $2,790 - $3,520
500 Added 18.36%
3,224 $20,000
Q2 2021

Aug 10, 2021

BUY
$5.19 - $6.73 $10,380 - $13,460
2,000 Added 276.24%
2,724 $16,000
Q1 2021

May 11, 2021

BUY
$5.74 - $9.67 $2,089 - $3,519
364 Added 101.11%
724 $4,000
Q3 2020

Nov 13, 2020

BUY
$5.73 - $8.11 $1,146 - $1,622
200 Added 125.0%
360 $2,000
Q1 2020

May 12, 2020

BUY
$3.45 - $7.95 $531 - $1,224
154 Added 2566.67%
160 $1,000
Q4 2019

Feb 07, 2020

BUY
$6.38 - $8.73 $38 - $52
6 New
6 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.96B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Rockefeller Capital Management L.P. Portfolio

Follow Rockefeller Capital Management L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

News

Stay updated on Rockefeller Capital Management L.P. with notifications on news.